The company aims to stay ahead of global market needs by investing in equipment and technologies to improve the productivity of its peptide assets
CordenPharma has announced the addition of a second 100 cm high-pressure chromatography column at its Colorado facility, to accommodate growth in the peptide therapeutic market.
In Q4 2020, the company announced an expansion of non-GMP capacity at its Centre of Excellence for Peptide Process Development in Frankfurt, Germany and a major increase in upstream capacity with the introduction of a 3000 L solid phase peptide synthesis (SPPS) vessel at its Colorado site.
Matthieu Giraud, PhD, Global Director of the Peptides, Lipids & Carbohydrates Platform said: “This additional column will provide the capacity to purify several tons of peptide annually, which in conjunction with our existing 100 and 80 cm columns, gives us more flexibility and redundancy to maximize supply security for all of our partners.”
The company aims to stay ahead of global market needs by investing in equipment and technologies to improve the productivity of its peptide assets, in particular via the deployment of innovative process analytical technology (PAT).
The column is already installed and will be qualified by the end of Q2 2021.
Together with the company’s Caponago site in Italy dedicated to injectable formulation development and drug product manufacturing, CordenPharma provides a vertically-integrated supply chain from regulated raw materials through intermediates, APIs, commercial-scale Drug Product manufacturing, finished dosage formulation, clinical trial services, & pharma logistics.
The Colorado site has 400 employees, and focuses on the development & manufacturing of APIs from laboratory-scale to commercialization at ton-scale, owing to its large-scale SPPS capabilities. The site has a track record in the large-scale manufacturing of peptides, the company says, where all potencies, including picogram levels, are managed.